PRLR hFc Chimera, Canine
PRLR HFc Chimera, Canine

The purity of PRLR hFc Chimera, Canine is greater than 95% as determined by SEC-HPLC.

PRLR HFc Chimera, Canine

PRLR hFc Chimera, Canine on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PRLR hFc Chimera, Canine

Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers.
Z04715
¥69,021.00

Ask us a question
Product Introduction
Species Canine
Protein Construction
PRLR (Gln25-Thr235)
Accession # XM_038663941.1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 53.89 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • PRLR HFc Chimera, Canine
    • PRLR HFc Chimera, Canine

    The purity of PRLR hFc Chimera, Canine is greater than 95% as determined by SEC-HPLC.

  • PRLR HFc Chimera, Canine
    • PRLR HFc Chimera, Canine

    PRLR hFc Chimera, Canine on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers.
Synonyms PRL-R; HPRL; MFAB; Prolactin R

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.